How gut bacteria educate our immune system and how cancer drugs can be remote-controlled

Physician and immunologist Dennis L. Kasper (81) of Harvard Medical School will receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2024, endowed with €120,000, in a ceremony held in Frankfurt’s Paulskirche today. The award recognizes his discovery of the first words of the biochemical language through which bacteria that populate our colon educate our immune system, thereby ensuring its healthy development. The Early Career Award goes to chemist Johannes Karges (31) from Ruhr University Bochum for his invention of a process with which highly effective chemotherapeutic agents can only accumulate in the tumor and can only be activated there by irradiation with light or ultrasound.

Leading immunologist Dr. Dennis L. Kasper, will be awarded the Paul Ehrlich and Ludwig Darmstaedter Prize for his revolutionary discovery on gut bacteria’s role in maintaining our immune health. Meanwhile, chemist Johannes Karges received recognition for designing an innovative chemo-process activated specifically at tumor locations using light or ultrasound.

Originamitteilung:

Physician and immunologist Dennis L. Kasper (81) of Harvard Medical School will receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2024, endowed with €120,000, in a ceremony held in Frankfurt’s Paulskirche today. The award recognizes his discovery of the first words of the biochemical language through which bacteria that populate our colon educate our immune system, thereby ensuring its healthy development. The Early Career Award goes to chemist Johannes Karges (31) from Ruhr University Bochum for his invention of a process with which highly effective chemotherapeutic agents can only accumulate in the tumor and can only be activated there by irradiation with light or ultrasound.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

Multiresistente Keime in die Knie zwingen

Fluorierte Lipopeptide als hochwirksame Antibiotika
Multiresistente bakterielle Infektionen, gegen die keine bekannten Antibiotika mehr helfen, sind eine ernsthafte globale Bedrohung. Ein chinesisches Forschungsteam stellt in der Zeitschrift Angewandte Chemie jetzt einen Ansatz vor, auf dessen Basis sich neuartige Antibiotika gegen resistente Keime entwickeln lassen. Sie basieren auf Eiweißbausteinen mit fluorierten Lipidketten.

Read More